18F-PI-2620 as a potential biomarker in progressive supranuclear palsy


  • 18F-PI-2620 PET imaging showed significantly higher binding in target regions in individuals with progressive supranuclear palsy (PSP) compared to controls, suggesting that it may aid in the diagnosis and differentiation of patients with suspected PSP.

Why this matters

  • Clinical assessments for early PSP lack sensitivity due to an overlap of symptoms with other neurodegenerative disorders such as corticobasal degeneration. Previous studies have shown that tau-PET imaging was able to differentiate patients with PSP from controls.

  • Identifying potential tau-PET imaging methods to differentiate between individuals with suspected PSP and controls may help to facilitate a more reliable diagnosis for PSP.